BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vuorio AF, Ojala J, Sarna S, Turtola H, Tikkanen MJ, Kontula K. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and Pvu II polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. Journal of Internal Medicine 1995;237:43-8. [DOI: 10.1111/j.1365-2796.1995.tb01138.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Kolovou GD, Kostakou PM, Anagnostopoulou KK. Familial hypercholesterolemia and triglyceride metabolism. International Journal of Cardiology 2011;147:349-58. [DOI: 10.1016/j.ijcard.2010.08.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
2 Hoffmann MM, Winkelmann BR, Wieland H, März W. The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs. Pharmacogenomics 2001;2:107-21. [DOI: 10.1517/14622416.2.2.107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
3 Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006;6:360-74. [PMID: 16550210 DOI: 10.1038/sj.tpj.6500384] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 6.7] [Reference Citation Analysis]
4 Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen TA. Stanol Ester Margarine Alone and With Simvastatin Lowers Serum Cholesterol in Families With Familial Hypercholesterolemia Caused by the FH–North Karelia Mutation. ATVB 2000;20:500-6. [DOI: 10.1161/01.atv.20.2.500] [Cited by in Crossref: 84] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
5 Sun X, Patel DD, Knight BL, Soutar AK. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. Atherosclerosis 1998;136:175-85. [DOI: 10.1016/s0021-9150(97)00181-0] [Cited by in Crossref: 64] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
6 Winkelmann BR, Hoffmann MM, März W. Lipid-Lowering Responses Modified by Genetic Variation. In: Wilkins MR, editor. Cardiovascular Pharmacogenetics. Berlin: Springer Berlin Heidelberg; 2004. pp. 107-47. [DOI: 10.1007/978-3-662-06214-2_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004;177:219-34. [PMID: 15530894 DOI: 10.1016/j.atherosclerosis.2004.09.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
8 Vuorio AF, Kovanen PT, Gylling H. Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge. Expert Review of Cardiovascular Therapy 2014;2:405-15. [DOI: 10.1586/14779072.2.3.405] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Chaves FJ, Real JT, García-García AB, Civera M, Armengod ME, Ascaso JF, Carmena R. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. J Clin Endocrinol Metab 2001;86:4926-32. [PMID: 11600564 DOI: 10.1210/jcem.86.10.7899] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
10 Etxebarria A, Benito-vicente A, Palacios L, Stef M, Cenarro A, Civeira F, Ostolaza H, Martin C. Functional Characterization and Classification of Frequent Low-Density Lipoprotein Receptor Variants. Human Mutation 2015;36:129-41. [DOI: 10.1002/humu.22721] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
11 García-garcía AB, González C, Real JT, Martín de Llano JJ, González-albert V, Civera M, Chaves FJ, Ascaso JF, Carmena R. Influence of microsomal triglyceride transfer protein promoter polymorphism −493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia: . Pharmacogenetics and Genomics 2005;15:211-8. [DOI: 10.1097/01213011-200504000-00004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
12 Naoumova RP, Marais AD, Mountney J, Firth JC, Rendell NB, Taylor GW, Thompson GR. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996;119:203-13. [PMID: 8808497 DOI: 10.1016/0021-9150(95)05649-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 2.7] [Reference Citation Analysis]
13 Sijbrands EJ, Lombardi M, Westendorp RG, Gevers Leuven JA, Meinders A, Van der Laarse A, Frants RR, Havekes LM, Smelt AH. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 1998;136:247-54. [DOI: 10.1016/s0021-9150(97)00216-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Leren TP, Hjermann I. Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene? Eur J Clin Invest 1995;25:967-73. [DOI: 10.1111/j.1365-2362.1995.tb01975.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
15 Galicia-Garcia U, Benito-Vicente A, Uribe KB, Jebari S, Larrea-Sebal A, Alonso-Estrada R, Aguilo-Arce J, Ostolaza H, Palacios L, Martin C. Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR. Sci Rep 2020;10:1727. [PMID: 32015373 DOI: 10.1038/s41598-020-58734-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Real JT, Chaves FJ, Ejarque I, García-garcía AB, Valldecabres C, Ascaso JF, Armengod ME, Carmena R. Influence of LDL receptor gene mutations and the R3500Q mutation of the apoB gene on lipoprotein phenotype of familial hypercholesterolemic patients from a South European population. Eur J Hum Genet 2003;11:959-65. [DOI: 10.1038/sj.ejhg.5201079] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
17 Vuorio AF, Turtola H, Piilahti KM, Repo P, Kanninen T, Kontula K. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler Thromb Vasc Biol 1997;17:3127-38. [PMID: 9409302 DOI: 10.1161/01.atv.17.11.3127] [Cited by in Crossref: 54] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
18 Koivisto U, Gylling H, Miettinen TA, Kontula K. Familial Moderate Hypercholesterolemia Caused by Asp235→Glu Mutation of the LDL Receptor Gene and Co-occurrence of a De Novo Deletion of the LDL Receptor Gene in the Same Family. ATVB 1997;17:1392-9. [DOI: 10.1161/01.atv.17.7.1392] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
19 Koeijvoets KC, Wiegman A, Rodenburg J, Defesche JC, Kastelein JJ, Sijbrands EJ. Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study. Atherosclerosis 2005;180:93-9. [PMID: 15823280 DOI: 10.1016/j.atherosclerosis.2004.10.042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
20 Nemati MH, Astaneh B. Optimal management of familial hypercholesterolemia: treatment and management strategies. Vasc Health Risk Manag 2010;6:1079-88. [PMID: 21191428 DOI: 10.2147/VHRM.S8283] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
21 Huxley RR, Hawkins MH, Humphries SE, Karpe F, Neil HA; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. Stroke 2003;34:22-5. [PMID: 12511745 DOI: 10.1161/01.str.0000047123.14312.3e] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
22 Roy G, Couture P, Genest J, Ruel I, Baass A, Bergeron J, Brisson D, Brunham LR, Cermakova L, Gaudet D, Khoury E, Laflamme N, Kennedy BA, Hegele RA, Drouin-Chartier JP. Influence of the LDL-receptor genotype on statin response in heterozygous familial hypercholesterolemia: insights from the Canadian FH Registry. Can J Cardiol 2021:S0828-282X(21)00822-9. [PMID: 34774719 DOI: 10.1016/j.cjca.2021.10.013] [Reference Citation Analysis]
23 Brorholt-petersen J, Jensen H, Raungaard B, Gregersen N, Faergeman O. LDL-receptor gene mutations and the hypocholesterolemic response to statin therapy: Pharmacogenetics in familial hypercholesterolemia. Clinical Genetics 2001;59:397-405. [DOI: 10.1034/j.1399-0004.2001.590604.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
24 Vergopoulos A, Knoblauch H, Schuster H. DNA Testing for Familial Hypercholesterolemia: Improving Disease Recognition and Patient Care. American Journal of PharmacoGenomics 2002;2:253-62. [DOI: 10.2165/00129785-200202040-00005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
25 Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 2005;112:3168-73. [PMID: 16286607 DOI: 10.1161/CIRCULATIONAHA.105.565507] [Cited by in Crossref: 53] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
26 Chaves FJ, Real JT, García-garcía AB, Puig O, Ordovas JM, Ascaso JF, Carmena R, Armengod ME. Large rearrangements of the LDL receptor gene and lipid profile in a FH Spanish population: LDLR gene mutations and lipid values in FH. European Journal of Clinical Investigation 2001;31:309-17. [DOI: 10.1046/j.1365-2362.2001.00823.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
27 Berberich AJ. The Power to Predict: Does LDLR mutation status determine statin responsiveness? Canadian Journal of Cardiology 2022. [DOI: 10.1016/j.cjca.2022.01.006] [Reference Citation Analysis]
28 Pavanello C, Pirazzi C, Bjorkman K, Sandstedt J, Tarlarini C, Mosca L, Romeo S, Calabresi L, Mancina RM. Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels. Journal of Clinical Lipidology 2019;13:778-787.e6. [DOI: 10.1016/j.jacl.2019.06.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
29 O’neill FH, Patel DD, Knight BL, Neuwirth CKY, Bourbon M, Soutar AK, Taylor GW, Thompson GR, Naoumova RP. Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia. ATVB 2001;21:832-7. [DOI: 10.1161/01.atv.21.5.832] [Cited by in Crossref: 51] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
30 Real JT, Chaves FJ, Civera M, García-García AB, Ascaso JF, Armengod ME, Carmena R. [Influence of FH Valencia 1 and 2 mutations of the LDL receptor gene on the response to simvastatin in subjects with molecularly defined heterozygous familial hypercholesterolemia in Spain]. Med Clin (Barc) 2001;116:81-5. [PMID: 11181283 DOI: 10.1016/s0025-7753(01)71731-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
31 Soljanlahti S, Autti T, Lauerma K, Raininko R, Keto P, Turtola H, Vuorio AF. Familial Hypercholesterolemia Patients Treated With Statins at No Increased Risk for Intracranial Vascular Lesions Despite Increased Cholesterol Burden and Extracranial Atherosclerosis. Stroke 2005;36:1572-4. [DOI: 10.1161/01.str.0000169920.64180.fa] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
32 Ordovas JM, Schaefer EJ. Treatment of dyslipidemia: Genetic interactions with diet and drug therapy. Curr Atheroscler Rep 1999;1:16-23. [DOI: 10.1007/s11883-999-0045-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
33 Long XJ, Yin RX, Li KL, Liu WY, Zhang L, Cao XL, Miao L, Wu DF, Htet Aung LH, Hu XJ. Low density lipoprotein receptor gene Ava II polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis 2011;10:34. [PMID: 21345210 DOI: 10.1186/1476-511X-10-34] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]